Article citationsMore>>

Doets, A.Y., Verboon, C., van den Berg, B., Harbo, T., Cornblath, D.R., Willison, H.J., Islam, Z., Attarian, S., Barroso, F.A., Bateman, K., Benedetti, L., van den Bergh, P., Casasnovas, C., Cavaletti, G., Chavada, G., Claeys, K.G., Dardiotis, E., Davidson, A., van Doorn, P.A., Feasby, T.E. and Galassi, G. (2018) Regional Variation of Guillain-Barré Syndrome. Journal of Neurology, Neurosurgery, and Psychiatry, 89, 125-131.

has been cited by the following article:

• TITLE: Miller Fisher Syndrome Induced by Chemotherapy in Known Case of Acute Lymphocytic Leukaemia: A Case Report

  AUTHORS: Musab Eltayeb, Musab Suliman, Amna Hajalsayed, Hisham Alamin, Alnour Alagib

  KEYWORDS: Guillain-Barre Syndrome Variant, Miller Fisher Syndrome, Chemotherapy, Acute Lymphocytic Leukaemia

  JOURNAL NAME: Open Journal of Internal Medicine, Vol.13 No.2, June 8, 2023

  ABSTRACT: Introduction: Guillain-Barre Syndrome (GBS) is an acute-onset autoimmune-mediated neuropathy. Guillain-Barre Syndrome can be divided into three subtypes: acute inflammatory demyelinating poly-radiculo-neuropathy (AIDP), acute motor axonal neuropathy (AMAN), and acute motor sensory axonal neuropathy (AMSAN). About 20% of patients with GBS develop respiratory failure and require mechanical ventilation. We are presenting a variant of GBS (Miller Fisher Syndrome, or MFS), which has been confirmed by nerve conduction studies along with the triad of ophthalmoplegia, ataxia, and areflexia. The objective of this study is to present a rare case of chemotherapy-induced GBS. Important clinic findings: A 25-year-old gentleman with acute lymphocytic leukemia on active chemotherapy treatment presented with lower limb weakness. This weakness started after his fifth chemotherapy session. After the sixth chemotherapy, he developed complete paralysis of the left lower limb. Later, he developed right lower limb paralysis. He was also complaining of eye dryness and incomplete closure of both eyes. While inpatient, he developed upper-limb weakness. His chemotherapy consisted of MESNA, cyclophosphamide, doxorubicin, vincristine, cyorabine, and methotrexate. He had ptosis and ophthalmoplegia in the left abducent and right oculomotor regions. He had bilateral facial nerve palsy. He was hypotonic with power grade 3 in the upper limbs and grade 0 in the lower limbs with areflexia. His sensation was intact in the upper limbs but lost in the lower limbs. His planter reflexes were mute. Diagnoses and Management: Intravenous immunoglobulins were given for 5 days. A nerve conduction study showed severe demyelinating sensorimotor polyradoculoneuropathy with secondary axonal loss. The triad of ataxia, ophthalmoplegia, and areflexia was consistent with MFS. The patient improved over the course of the hospital stay but did not reach full recovery. Conclusion: Although GBS is uncommon, it must be taken into account when making a differential diagnosis for any patient presenting with progressive weakness. Drug history is important in all GBS cases.